 NEW YORK, June 15, 2021 PRNewswire -- Brainstorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant andor allowance of a series of patents and patent applications. These patents and patent applications, which were grantedallowed in 2020 and 2021, are expected to provide broad protection for Brainstorms proprietary NurOwn MSC-NTF cells technology in territories including the U.S., E.U. 